by New research suggests that the immunotoxicity of chemotherapy in lipid nanoparticles (LNPs) can be mitigated through chemical conjugation, potentially improving the safety and efficacy of these therapeutic agents.
According to a recent study published in the journal ACS Nano, researchers have discovered that attaching specific chemical groups to the surface of LNPs can help reduce their interaction with the immune system, thereby minimizing unwanted immune responses and increasing the therapeutic potential of the chemotherapy drugs they carry.
The team, led by Dr. Xiaogang Zhang from the University of California, Riverside, used a model anticancer drug, doxorubicin, encapsulated in LNPs, and tested its immunotoxicity in mice. They found that the LNP-doxorubicin formulation caused significant immune activation, leading to liver damage and inflammation.
To address this issue, the researchers explored the use of chemical conjugation to modify the surface of the LNPs. They synthesized LNPs with a hydrophilic polymer, polyethylene glycol (PEG), attached to their surface via a cleavable linker. This modification allowed the LNPs to evade the immune system more effectively, reducing the immunotoxicity of the chemotherapy drug.
The results showed that the PEGylated LNP-doxorubicin formulation caused fewer immune responses and less liver damage compared to the non-PEGylated LNP-doxorubicin. The researchers also demonstrated that the PEGylation did not affect the drug’s anticancer efficacy.
These findings could have significant implications for the development of safer and more effective LNP-based chemotherapeutics. By optimizing the chemical conjugation of LNPs, researchers may be able to minimize unwanted immune responses and improve the therapeutic index of these drugs.
The study, “PEGylated Lipid Nanoparticles Mitigate the Immunotoxicity of Doxorubicin,” was published in the journal ACS Nano.
This research represents an important step forward in the field of nanomedicine, as it highlights the potential of chemical conjugation to improve the safety and efficacy of LNP-based chemotherapeutics. By continuing to explore new strategies for modifying the surface properties of LNPs, researchers may be able to develop next-generation therapeutics that can effectively target cancer cells while minimizing the risk of immunotoxicity.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
